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BRIEF REPORT
Clinical Effects and Antivenom Use for Snake Bite Victims
Treated at Three US Hospitals in Afghanistan
Jason D. Heiner, MD; Vikhyat S. Bebarta, MD; Shawn M. Varney, MD; Jason D. Bothwell, MD;
Aaron J. Cronin, PA-C
From the University of Washington, Seattle, WA (Dr Heiner); the San Antonio Military Medical Center, Fort Sam Houston, TX (Drs Heiner,
Bebarta, and Varney); the Madigan Army Medical Center, Joint Base Lewis-McCord, WA (Dr Bothwell); and the Womack Army Medical Center,
Fort Bragg, NC (Mr Cronin).
Objective.—Annually, more than 100,000 US and international military and civilian personnel work
in Afghanistan within terrain harboring venomous snakes. Current literature insufficiently supports
Afghan antivenom treatment and stocking guidelines. We report the clinical course and treatments for
snakebite victims presenting to US military hospitals in Afghanistan.
Methods.—All snakebite victims presenting to 3 US military emergency departments between July
2010 and August 2011 in northern and southern Afghanistan were examined via chart review. Case
information included patient demographics, snake description, bite details and complications, laboratory
results, antivenom use and adverse effects, procedures performed, and hospital course.
Results.—Of 17 cases, median patient age was 20 years (interquartile range [IQR], 12–30), 16 were
male, and 82% were Afghans. All bites were to an extremity, and median time to care was 2.8 hours
(IQR, 2–5.8). On arrival, 8 had tachycardia and none had hypotension or hypoxia. A viper was
implicated in 5 cases. Ten cases received at least 1 dose of polyvalent antivenom, most commonly for
coagulopathy, without adverse effects. Six received additional antivenom, 6 had an international
normalized ratio (INR) 4 10, and none developed delayed coagulopathy. Three received blood
transfusions. Hospital stay ranged from 1 to 4 days. None required vasopressors, fasciotomy, or other
surgery, and none died. All had resolution of marked coagulopathies and improved swelling and pain
on discharge.
Conclusions.—We report the largest series of snake envenomations treated by US physicians in
Afghanistan. Antivenom was tolerated well with improvement of coagulopathy and symptoms. All
patients survived with minimal advanced interventions other than blood transfusion.
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Introduction
The terrain of Afghanistan is inhabited by several
venomous snakes with the potential to produce a variety
of toxic effects including neurotoxicity, coagulopathies,
and tissue necrosis: these include vipers (such as the
saw-scaled viper, Echis carinatus) and the Oxus cobra
(Naja oxiana).1–3 Although nearby countries such as
Pakistan and India are reported by the World Health
Organization to possess the largest annual snakebite
mortalities in the world with a combined estimated
annual snakebite mortality of up to 70,000 deaths per
year, little is known about the burden of Afghan snake
envenomations.2–6 In addition to the indigenous popula-
tion, each year more than 100,000 US and international
civilians and military service members presently work in
Afghanistan and are at risk for this environmental
hazard.
Although snake envenomations occur continually
during warm weather in Afghanistan, little information
is available about these encounters and their subsequent
medical treatment. To date the most comprehensive
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report is a voluntary, cross-sectional survey of 390 US
military service members with primary duty assignment
to Afghanistan, which was administered after they had
departed the country.6 Although this study revealed 7
self-reported Afghanistan snake encounters and an
increased risk of snakebite in Afghanistan compared
with Iraq, no questions relating to clinical visits asso-
ciated with these encounters were asked.6 Modern US
military hospital facilities in Afghanistan frequently
possess emergency departments (EDs) with emergency
physicians, access to expert toxicology consultation, and
available polyvalent snake antivenoms. However, the
paucity of published reports of patients treated in these
facilities for Afghan snakebites is insufficient to support
guidance on hospital antivenom treatment and stocking
guidelines. In this investigation we sought to report the
clinical effects and treatments recorded for a series of
snakebite victims presenting to 3 US military hospital
EDs in Afghanistan.
Methods
All available medical records of all snakebite victims
treated at 3 US military hospital EDs in Afghanistan
between July 2010 and August 2011 were retrospec-
tively reviewed. Site hospitals functioned as high-
volume regional referral centers and were located in
northwest (Herat Province), northeast (Parwan Province),
and southern (Helmand Province) regions of the country
and represented the geographic variety of the Afghan
terrain. Patients (including international military coali-
tion forces and local Afghan individuals) either primarily
presented to or were transferred to their respective EDs
for medical care. The diagnosis of snakebite was
established by the emergency physician at the receiving
facility. All 3 sites had access to expert toxicology
consultation either at their respective hospitals or via
telephone consultation. Although existing treatment
guidelines included specific recommendations regarding
symptoms such as progressive local edema or pain,
coagulopathy, or marked systemic effects (such as
hypotension or anaphylaxis), the decision to give anti-
venom was at the discretion of the treating ED physician,
and antivenom products were not standardized across
facilities.
Emergency physicians used a standardized data col-
lection tool to extract available case information includ-
ing patient demographics; snake species (if known); bite
details including anatomic site, time to ED care, and
clinical finding at the site noted during hospitalization;
laboratory results; details of antivenom use including
type, doses given, and noted adverse effects; and notable
hospital course details including blood product
transfusion, vasopressor use, and surgical procedures
performed. Identification of the offending snake was
generally by patient report with the assistance of
zoological photographs of known Afghanistan snakes.
Missing or unavailable data were noted as “unknown,”
and compiled data were analyzed using descriptive
statistics. Institutional review board approval was
received for this retrospective analysis of clinical cases.
Results
A total of 17 snakebite cases were available and included
for data abstraction. Snakebite victims presented to site
EDs between the months of March and August of the
study period. Case distribution was 5 (29%) from Herat
Province, 4 (24%) from Parwan Province, and 8 (47%)
from Helmand Province. Median reported patient age
was 20 years (interquartile range [IQR], 12–30 years;
range, 7–69 years). Sixteen patients were male (94%),
and most (82%) were local Afghans. Two were enlisted
American military service members (US Army and US
Marine Corps). All bites were to an extremity, including
finger or hand (6%), arm (18%), foot or ankle (47%), and
leg (29%), and all were reported as legitimate in nature
after accidental contact. Pseudocerastes persicus and
E carinatus (multisquamatus or sochureki) was impli-
cated in 5 cases, N oxiana was identified by the patient in
1 case, and the remaining offending snake identities were
uncertain.
Median time from bite to ED care was 2.8 hours (IQR,
2–5.8 hours; range, 30 minutes to 24 hours). On ED
arrival 8 patients had tachycardia (heart rate 4 100
beats/min), and none had hypotension (systolic blood
pressure ranged from 104 to 168 mm Hg) or hypoxia
(SpO2 ranged from 97% to 100%). Reported laboratory
values revealed a range of hematologic disturbances
(Table). Nine (53%) patients were found to have a
leukocytosis (white blood cell count 4 10  109/L)
on arrival. Six patients had an international normalized
ratio (INR) 4 10, and 10 patients were treated with at
least 1 dose of intravenous polyvalent antivenom (Razi
Vaccine & Serum Research Institute, Iran; or Favirept,
Sanofi Pasteur SA, France), most commonly for a
persistent elevated INR. One patient who reported
envenomation by N oxiana received antivenom for an
INR 4 10 and painful extremity swelling. Those
patients who received an additional administration of
antivenom did so an average of 3.5 hours after the first
dose (range, 2.5–6 hours). No anaphylaxis, serum sick-
ness, or other adverse effects of antivenom treatment
were noted. No patients developed delayed-onset coa-
gulopathy after ED presentation. Three envenomated
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Table. Selected case details of snake bites treated with antivenom at 3 US hospitals in Afghanistan
Case No. Age
(y)
Reported Snake
Identity
Time: Bite to ED (h) Initial HCT
(%)
Initial Platelets
(109/L)
Initial INR Total AV
Doses
AV Typea Final
HCT (%)
Final Platelets
(109/L)
Final INR
1 13 Unk 6 39.3 331 412b 1 Razi 32.9b,c 215 1
2 60 Unk Unk 4.0 272 1.0 0 N/A Unk Unk Unk
3 7 Unk 24 35.6b 314 1.4b 0 N/A 32.5b 310 Unk
4 30 Unk 1 46.2 209 1.2 0 N/A Unk Unk Unk
5 20 Unk Unk 43.4 161 1.2 1 Razi 48.3c 175 1.2
6 19 Unk 3.5 43.5 360 1.6b 4 Favirept 48.5 304 1.4b
7 49 Unk 0.5 38.4 217 1.1 0 N/A Unk Unk Unk
8 23 Unk 3 43.6 91b 1.1 0 N/A Unk Unk Unk
9 20 Unk 0.5 Unk Unk Unk 0 N/A Unk Unk Unk
10 7 Echis 18 29.3b 290 410b 4 Favirept 30.2b,c 220 0.7
11 12 Pseudocerastes
or Echis
2 44.7 62b 410b 4 Favirept 39.7 203 1.2
12 22 Unk 2 42.7 218 1.2 0 N/A Unk Unk 1.3b
13 29 Pseudocerastes
or Echis
Unk 49.2 215 4.1b 4 Favirept 36.5 167 0.8
14 6 Pseudocerastes 5 33.5b 242 410b 4 Favirept 31.3b 332 1.6b
15 69 Naja oxiana 2.5 40.4 183 410 4 Favirept 39.7 159 1.7b
16 7 Pseudocerastes 12.5 32.1b 78b 1.0 1 Favirept 30.3b 251 1.0
17 30 Unk 2 41.7 316 1.8b 3 Favirept 43.9 309 1.0
AV, antivenom; Echis, Echis carinatus multisquamatus or Echis carinatus sochureki; ED, emergency department; HCT, hematocrit; INR, international normalized ratio; N/A, not applicable;
Pseudocerastes, Pseudocerastes persicus; Unk, unknown.
a Razi indicates Razi Vaccine & Serum Research Institute, Iran; Favirep indicates Favirept, Sanofi Pasteur SA, France.
b Indicates abnormal laboratory values.
c Notes the final hematocrit of the 3 patients who were transfused packed red blood cells as part of their treatment.
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patients received transfusions of packed red blood cells
for anemia.
The hospital length of stay for all patients ranged from
1 to 4 days. No patients required tracheal intubation,
vasopressor support, or fasciotomy or other surgery, and
none died. At hospital discharge, all patients had
resolution of marked coagulopathies (Table), and all
reported improved or resolved extremity swelling and
pain at discharge.
Discussion
We report the largest case series of Afghan snake
envenomations treated by US physicians. Similar to past
studies of envenomations in the Middle East and South-
west Asia, incidents occurred in the spring and summer
(mirroring both the poikilothermic nature of snakes and
increased outdoor human activities during these months),
and extremity injuries predominated.5–8 Unlike the
existing survey of Afghan snakebites and reports of
Israeli Defense Force and Saudi Arabia snakebite vic-
tims, our series included children and elders rather than
only adults or soldiers.6–8 Similar to our investigation,
these past reports revealed the low occurrence of death
of those patients seeking treatment as well as the low
occurrence of known adverse effects of antivenom
treatment.6–8
Congruent with the complex and sometimes unpre-
dictable effects of venom, a variety of clinical and
hematologic abnormalities were observed. Although
severe pain, coagulopathy, and edema were described,
marked improvement or resolution of these abnormalities
was noted in concert with administration of polyvalent
antivenom. In the United States, a similar association
with clinical improvement and low incidence of imme-
diate hypersensitivity reaction has been observed with
Crotalidae polyvalent immune Fab therapy after crotaline
snake envenomation.9 Additionally, fasciotomy,
amputation, or other surgical procedures were avoided
in this cohort of patients, as was the need for vasoactive
medications. Two patients with severely elevated INR
and anemia each received a single transfusion of packed
red blood cells in addition to antivenom, but were
hemodynamically stable, and required no further blood
products. Overall, these findings lend support to current
antivenom availability and practices of administration.
Four antivenoms were supplied to study site hospitals
and were potentially available to treat snake bites in the
region: Saudi Polyvalent Snake Antivenom (Saudi Arabia),
Razi Polyvalent Snake Antivenin (Iran), Favirept Poly-
valent Snake Antivenin (France), and Haffekine/VinsBio
Polyvalent Antivenom (India). These antivenoms contain
purified, equine-derived F(ab)2 fragments and are able to
treat a variety of the most commonly encountered vipers
and elapids (including cobras) in the region. By design, the
Razi (Iranian) antivenom may have the broadest single-
agent coverage of expected Afghan venomous snakes. In
our case series, the reported single envenomation by N
oxiana behaved clinically similar to other symptomatic
bites, resulting in extremity edema, erythema, pain, and
coagulopathy and resolving with administration of Favirept
Polyvalent Snake Antivenin. The effects of only 2 anti-
venoms were observed during the study period (Razi
Polyvalent Snake Antivenin and Favirept Polyvalent Snake
Antivenin); although the Razi antivenom has potentially
broader regional envenomation coverage by design,
including possible better coverage of Pseudocerastes, our
evidence does not favor one of these regionally available
antivenoms over the other.
Limitations to this investigation exist, which should be
noted. Although data extraction was structured, the
presence of source record variability and the investiga-
tion’s retrospective nature restrict the degree of patient
detail available for review, limit assurance of complete
patient data, and did not promote uniformity of data.
This report relies on the optimal management of these
snakebite victims, and care may have differed between
emergency and inpatient providers. Moreover, initial ED
management was not standardized, and providers in this
austere setting were often challenged by unfamiliarity
with the effects of these local venomous snakes and
accurate determination of comprehensive patient-specific
factors for treatment in light of commonly significant
cultural, language, and health literacy barriers of enve-
nomated Afghan patients. Patient cofounders such as
unknown or undocumented coexisting medical problems
may affect the generalizability of these findings. The
short patient follow-up (maximum 4 days of total
hospitalization) does not eliminate the presence of late
complications, including serum sickness-type reactions
that could have been attributed to antivenom adminis-
tration. Although most culprit snake identifications were
by local Afghans with presumed familiarity with local
wildlife, and identification was assisted by zoological
photos, the accuracy of the implicated snake species is
uncertain. Without more certain identification, stronger
conclusions cannot be made regarding the relative
effectiveness of the antivenoms used against particular
snake species.
Snakebites and snake envenomations in Afghanistan
affect the local and visiting international populations,
and currently, care rendered by US physicians is a
common occurrence. From this detailed case series, we
infer that present management of such patients, including
the use of regional polyvalent antivenom, appears to be
both safe and effective with evidence of good patient
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outcomes for those who reach emergency hospital care.
Future studies may seek to clarify physician-perceived
indications for antivenom use and lengthen the period of
follow-up for detection of delayed complications. As the
global and Afghan burden of snake envenomations
continues, forthcoming investigations may further the
individual and regional care and management of this
potentially deadly environmental encounter.
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